352 related articles for article (PubMed ID: 30630698)
1. Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan.
Hsu CT; Chang MH; Ho MC; Chang HH; Lu MY; Jou ST; Ni YH; Chen HL; Hsu HY; Wu JF
J Formos Med Assoc; 2019 Nov; 118(11):1537-1545. PubMed ID: 30630698
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
Huang JG; Tan MYQ; Quak SH; Aw MM
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
[TBL] [Abstract][Full Text] [Related]
4. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
[TBL] [Abstract][Full Text] [Related]
5. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
[TBL] [Abstract][Full Text] [Related]
6. Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease.
Weiner C; Weintraub L; Wistinghausen B; Tomaino J; Arnon R; Kerkar N; Miloh T
Pediatr Transplant; 2012 Aug; 16(5):458-64. PubMed ID: 22554096
[TBL] [Abstract][Full Text] [Related]
7. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
Soriano-López DP; Alcántar-Fierros JM; Hernández-Plata JA; González-Jorge AL; Velázquez-Ramos S; Flores-Hernández MA; Fuentes V; Castañeda P; Nieto J; Sánchez JL; López B; Valencia-Mayoral P; Varela-Fascinetto G
Transplant Proc; 2016 Mar; 48(2):654-7. PubMed ID: 27110023
[TBL] [Abstract][Full Text] [Related]
8. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
9. Posttransplant lymphoproliferative disorder in pancreas transplantation: a single-center experience.
Paraskevas S; Coad JE; Gruessner A; Kandaswamy R; Humar A; Sutherland DE; Gruessner RW
Transplantation; 2005 Sep; 80(5):613-22. PubMed ID: 16177635
[TBL] [Abstract][Full Text] [Related]
10. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
[TBL] [Abstract][Full Text] [Related]
11. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
[TBL] [Abstract][Full Text] [Related]
12. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
13. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
14. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
Offor UT; Bacon CM; Roberts J; Powell J; Brodlie M; Wood K; Windebank KP; Flett J; Hewitt T; Rand V; Hasan A; Parry G; Gennery AR; Reinhardt Z; Bomken S
J Heart Lung Transplant; 2021 Jan; 40(1):24-32. PubMed ID: 33339556
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
16. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation].
Deng Z; Jiang L; Zhou T; Shen C; Chen Q; Xia Q
Zhonghua Er Ke Za Zhi; 2014 Aug; 52(8):579-82. PubMed ID: 25224233
[TBL] [Abstract][Full Text] [Related]
17. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, risks, and outcomes of post-transplant lymphoproliferative disease >3 years after pediatric heart transplant: A multicenter analysis.
West SC; Friedland-Little JM; Schowengerdt KO; Naftel DC; Pruitt Freeze E; Smith KS; Urschel S; Michaels MG; Kirklin JK; Feingold B
Clin Transplant; 2019 May; 33(5):e13521. PubMed ID: 30861200
[TBL] [Abstract][Full Text] [Related]
20. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
